Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Schmidinger, Manuela; Zielinski, Christoph; Vogl, Ursula; Bojic, Andja; Bojić, Marija; Schukro, Christoph; Ruhsam, Marquerite; Hejna, Michael; Schmidinger, Herwig

doi:10.1200/jco.2007.15.6331

Public

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Published in Journal of Clinical Oncology • Oct 7, 2008

Authors:

Manuela Schmidinger

Christoph Zielinski

Ursula Vogl

Abstract

PURPOSE: Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) that have considerable efficacy in metastatic renal cell carcinoma. TKI-associated cardiotoxicity was reported in approximately 10% of the patients. Detailed cardiovascular monitoring during TKI treatment may reveal early signs o...

Subject

Medicine

Sunitinib

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!